Trademark: 97978222
Word
ALLUCENT
Status Date
Tuesday, July 30, 2024
Registration Number
7464174
Registration Date
Tuesday, July 30, 2024
Filing Date
Wednesday, April 20, 2022
Published for Opposition
Tuesday, September 5, 2023
41 Training and development in the field of conducting clinical trials, namely, conducting tutorials, seminars and workshops in the field of clinical trials; training in the field of computer software support, namely, conducting tutorials, seminars and workshops in the field of software support
35 Data management, namely, abstraction services in the nature of extracting and summarizing information from clinical trial records and collection of medical data from clinical tests and records for business purposes; Market research and business marketing consulting services in the pharmaceutical, biotechnology, medical device, and diagnostics industries; Data management, namely, the management for others of databases of patient health data
45 Development of regulatory compliance strategies in the field of medical research, namely, regulatory compliance consulting in the field of drug, biologic, cosmetic and medical device development
42 Cloud computing featuring software that allows users to collect, review, analyze and report on clinical research; technical support services, namely, installation and remote administration of software, and troubleshooting of software problems and hosted software applications, all for use in connection with medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; cloud computing featuring software for providing telehealth, telemedicine, remote care and virtual health care services to patients; cloud computing featuring software that allows users to collect, track, retrieve, validate, summarize, statistically analyze and present data used in the areas of medical research and product regulatory approval, environmental health, health care, and in relation to the design, research, development, and testing of new medical products and devices; Cloud computing featuring software to aggregate, integrate, transfer and manage data generated from home health and remote monitoring devices and applications and health-related smart-phone applications; Cloud computing featuring software that provides integrated workflows, analytics, visualizations, and reporting features to deliver, process, analyze, elevate, and display patient-generated health data; Cloud computing featuring software that integrates remotely collected health data into databases, systems, platforms, applications, and software that inform clinical research, remote monitoring, and care management; technical consulting services, namely, evaluating the safety of pharmaceutical, medical, cosmetic and consumer devices and products in clinical development or in commercial production; Consulting services for others in the fields of design, planning, implementation and project management of clinical trials; Scientific analysis of statistical and qualitative data relating to clinical trials for pharmaceuticals, biotechnology, medical devices and diagnostics for scientific research and for the development of pharmaceutical, biotechnology, medical device and diagnostic products and methods of use of such devices and products
The mark consists of the word ALLUCENT appearing dark blue with the inside space of the capital letter "A" filled in with an orange triangle in the top half of the "A" that extends between the two outside lines of the "A" and a gold trapezoid in the bottom half of the "A" and the remaining letters appearing in dark blue lowercase.
The color(s) dark blue, orange and gold is/are claimed as a feature of the mark.
Apr 23, 2022
New Application Entered
Nov 21, 2022
Letter Of Protest Evidence Forwarded
Jan 4, 2023
Letter Of Protest Evidence Reviewed-No Further Action Taken
Jan 6, 2023
Non-Final Action E-Mailed
Apr 6, 2023
Teas Response To Office Action Received
Apr 6, 2023
Teas/Email Correspondence Entered
Apr 26, 2022
New Application Office Supplied Data Entered
Apr 27, 2022
Notice Of Design Search Code E-Mailed
Dec 28, 2022
Assigned To Examiner
Jan 6, 2023
Notification Of Non-Final Action E-Mailed
Jan 6, 2023
Non-Final Action Written
Apr 6, 2023
Correspondence Received In Law Office
May 16, 2023
Final Refusal Written
May 16, 2023
Notification Of Final Refusal Emailed
Jun 21, 2023
Correspondence Received In Law Office
Jun 22, 2023
Teas/Email Correspondence Entered
Jul 3, 2023
Approved For Pub - Principal Register
Jul 13, 2023
Previous Allowance Count Withdrawn
Jul 13, 2023
Withdrawn From Pub - Senior Attorney Request
Jul 29, 2023
Examiners Amendment -Written
Jul 29, 2023
Notification Of Examiners Amendment E-Mailed
Jul 29, 2023
Examiners Amendment E-Mailed
Jul 29, 2023
Examiner's Amendment Entered
Jul 29, 2023
Approved For Pub - Principal Register
Aug 16, 2023
Notification Of Notice Of Publication E-Mailed
Sep 5, 2023
Published For Opposition
Sep 5, 2023
Official Gazette Publication Confirmation E-Mailed
Oct 31, 2023
Noa E-Mailed - Sou Required From Applicant
Mar 26, 2024
Sou Extension 1 Granted
Mar 26, 2024
Sou Teas Extension Received
Mar 26, 2024
Sou Extension 1 Filed
Mar 27, 2024
Notice Of Approval Of Extension Request E-Mailed
Apr 4, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 4, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 4, 2024
Teas Change Of Correspondence Received
Apr 4, 2024
Teas Withdrawal Of Attorney Received-Firm Retains
Apr 11, 2024
Divisional Request Received
Apr 11, 2024
Teas Change Of Owner Address Received
Apr 11, 2024
Teas Change Of Correspondence Received
Apr 11, 2024
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 11, 2024
Teas Statement Of Use Received
Apr 11, 2024
Teas Request To Divide Received
May 2, 2024
Case Assigned To Intent To Use Paralegal
May 16, 2023
Final Refusal E-Mailed
Jun 21, 2023
Teas Request For Reconsideration Received
Apr 11, 2024
Use Amendment Filed
May 21, 2024
Divisional Processing Complete
May 21, 2024
Statement Of Use Processing Complete
Jun 25, 2024
Assigned To Examiner
Jun 25, 2024
Allowed Principal Register - Sou Accepted
Jun 25, 2024
Notice Of Acceptance Of Statement Of Use E-Mailed
Jul 30, 2024
Registered-Principal Register
Jul 30, 2024
Notice Of Registration Confirmation Emailed
Trademark Alertz updated from USPTO on 2030-01-24
